This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining varlilumab and atezolizumab. Phase l of the study will enroll patients with a number of tumor types; Phase ll will enroll only patients with renal cell carcinoma (RCC).* *Note: This Study was terminated prior to initiation of Phase II
Terminated
Phase 1
| Drug | Synonyms | Arms |
|---|---|---|
| Combination of Varlilumab and Atezolizumab | Varlilumab and Atezolizumab |
Varlilumab is a fully human monoclonal antibody that binds to a molecule called CD27 found on
certain immune cells and may act to promote anti-tumor effects.
Atezolizumab is an engineered anti-PD-L1 antibody.
This study will evaluate the safety, tolerability and efficacy of the anti-CD27 antibody
varlilumab in combination with atezolizumab.
Eligible patients that enroll in the dose escalation portion of the study will be assigned to
one of three dose levels of varlilumab in combination with 1200 mg of atezolizumab. The first
phase of the study will enroll up to 18 patients and test the safety profile of the
combination of varlilumab and atezolizumab in patients with various tumor types and determine
which dose of varlilumab will be studied in Phase ll* of the study which will enroll only
patients with RCC.
*Note: This Study was terminated prior to initiation of Phase II.
All patients enrolled in the study will be closely monitored to determine if there is a
response to the treatment as well as for any side effects that may occur.
| Name | Type | Description | Interventions |
|---|---|---|---|
| Varlilumab and Atezolizumab | Experimental |
|
Inclusion Criteria:
1. Unresectable stage lll or IV, histologically confirmed diagnosis of one of the
following solid tumors:
- Phase l: Melanoma, RCC, triple negative breast cancer, bladder cancer, head and
neck cancer or non-small cell lung cancer.
2. Documented progressive disease based on radiographic, clinical or pathologic
assessment during or subsequent to last therapy.
3. Progressed or intolerant to at least 1 approved prior anticancer regimen.
4. Measurable (target) disease.
5. Life expectancy ≥ 12 weeks.
6. If of childbearing potential (male or female), agrees to practice an effective form of
contraception during study treatment and for at least 90 days following last treatment
dose.
7. Must have available tumor tissue and consent to biopsy while on study.
8. Patients with asymptomatic treated CNS metastasis may be enrolled after discussion
with the Medical Monitor.
9. ECOG of 0 or 1.
Exclusion Criteria:
1. Prior therapy with varlilumab or with an anti-CD27 antibody.
2. Previous treatment with anti-PD-1, anti-PD-L1 or anti-PD-L2 therapy.
3. Use of any experimental immunotherapy.
4. Receipt of anti-CTLA-4 targeted therapies or other checkpoint or co-stimulatory
therapy within 3 months prior to start of study treatment.
5. Chemotherapy within 21 days or at least 5 half-lives (whichever is shorter) prior to
the planned state of study treatment.
6. Systemic radiation therapy within 4 weeks, prior focal radiotherapy within 2 weeks, or
radiopharmaceuticals (strontium, samarium) within 8 weeks prior to the first dose of
study treatment.
7. Use of immunosuppressive medications within 4 weeks or systemic corticosteroids within
2 weeks prior to first dose of study treatment.
8. Other prior malignancy, except for adequately treated basal or squamous cell skin
cancer or in situ cancers; or any other cancer from which the patient has been
disease-free for at least 3 years.
9. Active, untreated CNS metastases.
10. Active autoimmune disease or a documented history of autoimmune disease.
11. Active diverticulitis.
12. Significant cardiovascular disease including CHF, leptomeningeal disease, poorly
controlled hypertension, or an MI within 6 months prior to dosing.
13. Known alcohol or drug abuse.
| Maximum Eligible Age: | N/A |
| Minimum Eligible Age: | 18 Years |
| Eligible Gender: | All |
| Healthy Volunteers: | No |
| Measure: | Phase l: Safety and tolerability of varlilumab in combination with atezolizumab as measured by incidence of drug related adverse events (AEs), serious drug related AEs, dose-limiting toxicities and laboratory test abnormalities. |
| Time Frame: | Safety follow-up is 70 days from last study drug dose. |
| Safety Issue: | |
| Description: |
| Phase: | Phase 1 |
| Primary Purpose: | Interventional |
| Overall Status: | Terminated |
| Lead Sponsor: | Celldex Therapeutics |
April 30, 2018
